Related Experiment Video

Updated: Aug 10, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

[Ribavirin treatment of children with respiratory syncytial virus bronchiolitis]

C Lindgren1, J Grøgaard

  • 1Barneavdelingen Aker sykehus, Oslo.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|June 30, 1994
PubMed

Insights

Ribavirin offers a new treatment for severe respiratory syncytial virus bronchiolitis in infants when standard therapies fail. This antiviral drug effectively reduced viral shedding and improved infant oxygenation and clinical outcomes.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Pharmacology

Background:

  • Severe respiratory syncytial virus (RSV) bronchiolitis in infants traditionally managed with bronchodilators and corticosteroids.
  • Limited effective pharmacological options existed for severe cases.
  • The introduction of ribavirin presented a novel antiviral therapeutic approach.

Observation:

  • A case study of a three-week-old infant with severe RSV bronchiolitis in Norway.
  • This infant received ribavirin treatment when conventional therapies were insufficient.
  • This represents one of the few documented cases of ribavirin use in Norway for this condition.

Findings:

  • Ribavirin treatment demonstrated success in this infant.
  • The drug was shown to reduce viral shedding.
  • Significant improvements in oxygenation and overall clinical course were observed.

Implications:

  • Ribavirin provides a potential new therapeutic option for severe RSV bronchiolitis in infants.
  • Further critical evaluation of cost-benefit and safety is necessary before widespread adoption.
  • This case highlights the potential of antiviral therapy in managing severe pediatric respiratory infections.

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...